Enoxaparin dosing (Clexane) π
Enoxaparin (Clexane) dosing calculator for VTE prophylaxis and treatment: weight and CrCl-based doses aligned to HSE NCG-VTE and common Irish ward practice.
Enoxaparin (Clexane) dosing
HSE NCG-VTE guidelineUse CockcroftβGault for dose adjustment; eGFR is not equivalent.
Enter weight to see suggested doses.
Guidance only. Prophylaxis table reflects common Irish ward practice; treatment per HSE NCG-VTE. Product SPC, local formulary, and specialist advice take precedence.
Prophylaxis reference table
Weight band Γ creatinine clearance. Highlighted dose matches your inputs above.
Creatinine clearance
>30 ml/min
- <50 kg20 mgOD
- 50β100 kg40 mgOD
- 101β150 kg40 mgBD
- >150 kg60 mgBD
Creatinine clearance
15β30 ml/min
- <50 kg20 mgOD
- 50β100 kg20 mgOD
- 101β150 kg40 mgOD
- >150 kg60 mgOD
Creatinine clearance
<15 ml/min
- <50 kgConsultant
- 50β100 kg20 mgOD
- 101β150 kg20 mgOD
- >150 kgConsultant
ODOnce dailyBDTwice dailyConsultantSeek senior advice
π Overview
- Enoxaparin is the most commonly used LMWH in Irish hospitals for VTE prophylaxis and treatment.
- Use CockcroftβGault creatinine clearance for dose adjustment β eGFR is not equivalent.
- Always complete a VTE risk assessment and check bleeding risk before prescribing.
π Prophylaxis (summary)
- Doses depend on weight band and CrCl β see calculator and reference table.
- Typical standard prophylaxis: 40 mg once daily for 50β100 kg if CrCl >30 ml/min.
- Higher weights and renal impairment use reduced or less frequent dosing β calculator applies the weight/CrCl table.
π Treatment (summary)
- CrCl β₯30 ml/min: 1 mg/kg twice daily OR 1.5 mg/kg once daily β select based on thrombotic vs bleeding risk (HSE NCG-VTE).
- CrCl 15β30 ml/min: 1 mg/kg once daily and seek specialist advice.
- CrCl <15 ml/min: no standard dose β consultant / haematology input.
- Treatment doses are rounded to the nearest 10 mg in the calculator β verify with pharmacy and local protocol.
β οΈ Before prescribing
- Check platelets, renal function, weight, active bleeding, and heparin allergy / HIT history.
- Review concurrent anticoagulants, neuraxial procedures, and perioperative plans.
- Document indication, intended duration, and plan for transition to oral anticoagulation where appropriate.
π Related
Disclaimer
- Educational aid only. Prescribing remains your professional responsibility; confirm every dose with local policy, the product SPC (HPRA), and specialist advice where needed.
Note Template
Ready-to-use clinical note structure
π 23 / 08 / 2026 β 03:01 ATRP re: enoxaparin (Clexane) Patient: [age] [sex] Admission Dx: [reason for admission] PMHx: [VTE, bleeding, renal disease] π§Ύ Hx: β’ Indication: [VTE prophylaxis / DVT / PE treatment] β’ Weight: [__] kg Β· CrCl: [__] ml/min (CockcroftβGault) β’ Bleeding risk / contraindications reviewed: [yes/no] π Plan: β’ Enoxaparin [__] mg [OD / BD] subcutaneous β’ VTE risk assessment completed β’ Duration: [__] β transition to DOAC/warfarin if treatment β’ Anti-Xa / haematology review: [if indicated] π€ [Your Name], [Role] IMC: _______